Specimen record — masthead
About This Site
Medicine Retatrutide keeps a specimen record of the literature. Not a clinic. Not a pharmacy. Not a prescription service.
What this site is
Medicine Retatrutide keeps a specimen record of the peer-reviewed research literature on retatrutide (LY3437943), logging each study the way an apothecary logs a specimen. Nothing is sold, supplied, or dispensed here; no clinician is on staff; and no line on the site is medical advice, a prescription, or a treatment recommendation.
The 'medicine' in the domain name is a vantage — the perspective a pharmacopeia or apothecary's specimen record takes toward the literature — not a claim to offer medical services. This is a reading of the record, not a medical provider.
The site names no person as its author or editor. No real individual's name, credentials, or photograph is claimed here. It is an editorial publication, not a personal practice.
What we document
The retatrutide research record to date: Phase 1b first-in-human pharmacokinetics, Phase 2 obesity and diabetes trials, the MASLD (fatty liver) substudy, and the ongoing Phase 3 TRIUMPH program. Structural pharmacology from cryo-EM work. Pipeline reviews from expert clinical pharmacologists.
We document what was measured, what was found, and what remains open. We do not speculate beyond published data. Investigational status is stated wherever relevant — retatrutide is not approved, and no page on this site implies otherwise.
The editorial angle for this site is pharmacokinetics: the half-life, the structural basis of albumin binding, the dose-escalation rationale, the routes studied. That lens shapes which aspects of the literature receive the deepest treatment.
What we are not
This is no clinic, telehealth service, or pharmacy. It offers no consultations, diagnoses, prescriptions, or treatment plans. It supplies and links to no vendor of retatrutide or any other compound, and it prints no reconstitution instructions or dosing guidance.
Retatrutide is investigational; the FDA has not approved it. Any gray-market material sold as retatrutide is unregulated and of unverified identity, and this site does not facilitate access to that market.
If you are looking for a clinical trial: ClinicalTrials.gov (search 'LY3437943' or 'retatrutide') lists active TRIUMPH trial sites. That is the only legitimate current access route for retatrutide.